Crossmark

Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs growth and chemosensitizes embryonal and alveolar rhabdomyosarcoma cell lines

Crossref DOI link: https://doi.org/10.1007/s11010-025-05336-6

Published Online: 2025-06-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Codenotti, Silvia

Lauschke, Volker M.

Casella, Emma V.

Andersson, Daniel C.

Fanzani, Alessandro

Gastaldello, Stefano
Funding

Funding for this research was provided by:

Fondazione Umberto Veronesi

Karolinska Institutet (2022-02802, 2022-02802)

Erik och Edith Fernströms Stiftelse för Medicinsk Forskning (2022-00596)

Karolinska Institute
License Information

Text and Data Mining valid from 2025-06-23

Version of Record valid from 2025-06-23
More Information

Article History

Received: 12 March 2025

Accepted: 5 June 2025

First Online: 23 June 2025

Declarations

:

: V.M.L. is CEO and shareholder of HepaPredict AB, as well as shareholder and co-founder of Shanghai Hepo Biotechnology Ltd.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below